DE69525544D1 - Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose - Google Patents
Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen skleroseInfo
- Publication number
- DE69525544D1 DE69525544D1 DE69525544T DE69525544T DE69525544D1 DE 69525544 D1 DE69525544 D1 DE 69525544D1 DE 69525544 T DE69525544 T DE 69525544T DE 69525544 T DE69525544 T DE 69525544T DE 69525544 D1 DE69525544 D1 DE 69525544D1
- Authority
- DE
- Germany
- Prior art keywords
- multiple sclerosis
- human
- protein
- myeline
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34207894A | 1994-11-18 | 1994-11-18 | |
PCT/US1995/014402 WO1996016085A1 (en) | 1994-11-18 | 1995-11-16 | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69525544D1 true DE69525544D1 (de) | 2002-03-28 |
DE69525544T2 DE69525544T2 (de) | 2002-08-22 |
Family
ID=23340234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69525544T Expired - Fee Related DE69525544T2 (de) | 1994-11-18 | 1995-11-16 | Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose |
Country Status (9)
Country | Link |
---|---|
US (4) | US6369033B1 (de) |
EP (2) | EP0792286B1 (de) |
JP (1) | JPH10509714A (de) |
AT (1) | ATE213499T1 (de) |
AU (1) | AU721898B2 (de) |
CA (1) | CA2205532A1 (de) |
DE (1) | DE69525544T2 (de) |
MX (1) | MX9703642A (de) |
WO (1) | WO1996016085A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US7090982B2 (en) | 1991-10-22 | 2006-08-15 | The Governors Of The University Of Alberta | Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient |
PT863155E (pt) * | 1992-04-09 | 2002-07-31 | Autoimmune Inc | Supressao da proliferacao das celulas t utilizando fragmentos peptidicos da proteina basica da mielina |
AU4278296A (en) * | 1994-10-25 | 1996-05-15 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
WO1996016085A1 (en) * | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
WO1996028470A2 (en) * | 1995-03-09 | 1996-09-19 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
AU1874997A (en) * | 1996-02-15 | 1997-09-02 | Pangenetics B.V. | Molecules for the induction of immunological tolerance |
US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
US6541608B1 (en) * | 1999-02-23 | 2003-04-01 | Baylor College Of Medicine | T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
CA2445640A1 (en) * | 2001-03-23 | 2002-10-03 | John Matsoukas | Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms) |
US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
EP2363710B1 (de) * | 2002-08-08 | 2015-07-01 | Baylor College Of Medicine | Isolierung und identifizierung von t-zellen |
AU2006236294A1 (en) | 2005-04-19 | 2006-10-26 | Eli Lilly And Company | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
EP2420833B1 (de) * | 2006-05-05 | 2015-09-02 | Opexa Therapeutics | T-Zell Vakzin |
PL2949666T3 (pl) | 2008-12-19 | 2019-07-31 | Biogen International Neuroscience Gmbh | Ludzkie przeciwciała przeciwko alfa-synukleinie |
WO2012150495A1 (en) | 2011-05-05 | 2012-11-08 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
CN103102393B (zh) * | 2013-01-30 | 2015-01-07 | 北京大学 | 一种多肽及其在制备抑郁症治疗药物中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
ES2107459T3 (es) * | 1990-03-02 | 1997-12-01 | Autoimmune Inc | Mejora de la regulacion represora de enfermedades autoinmunes por administracion oral o enteral de autoantigenos. |
US5858980A (en) * | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
WO1992021367A1 (en) * | 1991-05-31 | 1992-12-10 | Arthur Allen Vandenbark | T cell receptor peptides as therapeutics for immune-related disease |
CA2053799C (en) * | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
PT863155E (pt) * | 1992-04-09 | 2002-07-31 | Autoimmune Inc | Supressao da proliferacao das celulas t utilizando fragmentos peptidicos da proteina basica da mielina |
AU695801B2 (en) * | 1993-09-22 | 1998-08-20 | Board Of Trustees Of The Leland Stanford Junior University | Interaction of T-cell receptors and antigen in autoimmune disease |
US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
WO1996016085A1 (en) * | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
-
1995
- 1995-11-16 WO PCT/US1995/014402 patent/WO1996016085A1/en active IP Right Grant
- 1995-11-16 EP EP95942842A patent/EP0792286B1/de not_active Expired - Lifetime
- 1995-11-16 CA CA002205532A patent/CA2205532A1/en not_active Abandoned
- 1995-11-16 DE DE69525544T patent/DE69525544T2/de not_active Expired - Fee Related
- 1995-11-16 JP JP8516910A patent/JPH10509714A/ja not_active Ceased
- 1995-11-16 AT AT95942842T patent/ATE213499T1/de not_active IP Right Cessation
- 1995-11-16 AU AU44057/96A patent/AU721898B2/en not_active Ceased
- 1995-11-16 EP EP01115315A patent/EP1172376A1/de not_active Withdrawn
-
1997
- 1997-05-16 MX MX9703642A patent/MX9703642A/es not_active Application Discontinuation
- 1997-10-20 US US08/953,937 patent/US6369033B1/en not_active Expired - Fee Related
-
2001
- 2001-11-19 US US09/989,476 patent/US6489299B2/en not_active Expired - Fee Related
-
2002
- 2002-10-11 US US10/270,707 patent/US6740638B2/en not_active Expired - Fee Related
-
2004
- 2004-04-08 US US10/820,983 patent/US20040214775A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0792286A1 (de) | 1997-09-03 |
AU721898B2 (en) | 2000-07-20 |
US6740638B2 (en) | 2004-05-25 |
EP1172376A1 (de) | 2002-01-16 |
US20030114380A1 (en) | 2003-06-19 |
AU4405796A (en) | 1996-06-17 |
CA2205532A1 (en) | 1996-05-30 |
WO1996016085A1 (en) | 1996-05-30 |
JPH10509714A (ja) | 1998-09-22 |
ATE213499T1 (de) | 2002-03-15 |
US20020058627A1 (en) | 2002-05-16 |
EP0792286B1 (de) | 2002-02-20 |
MX9703642A (es) | 1998-11-29 |
DE69525544T2 (de) | 2002-08-22 |
US20040214775A1 (en) | 2004-10-28 |
US6489299B2 (en) | 2002-12-03 |
US6369033B1 (en) | 2002-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69525544D1 (de) | Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose | |
ATE266043T1 (de) | Peptidanaloge des menschlichen basischen myelinproteins | |
AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
DE3585556D1 (de) | Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten. | |
ES2150983T3 (es) | Productos proteicos bactericidas estables que incrementan la permeabilidad y composiciones farmaceuticas que los contienen. | |
DE3852636D1 (de) | Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2). | |
ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
HUT49891A (en) | Process for production of peptides with antiaggregation effect and medical compositions containing them | |
OA06421A (fr) | Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides. | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
ATE377026T1 (de) | Behandlung von fettleibigkeit | |
ATE60062T1 (de) | Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren. | |
KR880013977A (ko) | 항응고제인 사이클릭 펩타이드 | |
DE69430416T2 (de) | Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen | |
DK34590A (da) | Biologisk aktive molekyler | |
ATE92078T1 (de) | Pharmakologisch aktive peptide. | |
KR890700673A (ko) | 돼지 성장호르몬 아날로그 | |
ATE27822T1 (de) | Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus. | |
DE3162674D1 (en) | A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it | |
KR920700224A (ko) | 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |